Cancer Types, Treatment and Research
Diabetes Drug Kills Cancer Stem Cells in Combination Treatment in Mice
Philadelphia, PA (Vocus) September 14, 2009 -- In a one-two punch, a familiar diabetes drug reduced tumors faster and prolonged remission in mice longer than chemotherapy alone by targeting cancer stem cells, Harvard Medical School researchers report in the September 14 online first edition of Cancer Research (http://cancerres.aacrjournals.org/cgi/rapidpdf/0008-5472.CAN-09-2994v1), a journal of the American Association for Cancer Research.
“We have found a compound selective for cancer stem cells,” said lead researcher Kevin Struhl, Ph.D., the David Wesley Gaiser professor of biological chemistry and molecular pharmacology at Harvard Medical School. “What’s different is that ours is a first-line diabetes drug.”
These findings add to a growing body of preliminary evidence in cells, mice and people that metformin may improve breast cancer outcomes in people. In this study, the diabetes drug seemed to work independently of its ability to improve insulin sensitivity and lower blood sugar and insulin levels, all of which are also associated with better breast cancer outcomes.
The results fit within the cancer stem cell hypothesis, an intensely studied idea that small subsets of cancer cells have a special power to initiate tumors, fuel tumor growth and promote recurrence of cancer. Cancer stem cells appear to resist conventional chemotherapies, which kill the bulk of the tumor.
“There is a big desire to find drugs specific to cancer stem cells,” said Struhl. “The cancer stem cell hypothesis says you cannot cure cancer unless you also get rid of the cancer stem cells. From a purely practical point of view, this could be tested in humans. It’s already [in use as a first-line diabetes drug.”
The possible usefulness of a diabetes drug against cancer lends credence to an emerging idea that, in the vast and complex alphabet soup of molecular interactions within cells, a relatively few biological pathways will turn out to be most important for many different diseases, Struhl suggested.
In experiments led by postdoctoral fellows Heather Hirsch, Ph.D., and Dimitrios Iliopoulos, Ph.D., the combination of metformin and the cancer drug doxorubicin killed human cancer stem cells and non-stem cancer cells in culture. The researchers used four genetically distinct breast cancer cell lines.
In mice, pretreatment with metformin prevented the otherwise dramatic ability of human breast cancer stem cells to form tumors. In other mice where tumors took hold for 10 days, the combination therapy also reduced tumor mass more quickly and prevented relapse for longer than doxorubicin alone. In the two months between the end of treatment and the end of the experiment, tumors regrew in the mice treated with chemotherapy alone, but not in those who received both drugs. Metformin was ineffective in treating tumors when used alone.
“This is an exciting study,” said Jennifer Ligibel, M.D., a medical oncologist at the Dana-Farber Cancer Institute and a Harvard Medical School instructor in medicine. Ligibel and colleagues at the National Cancer Institute of Canada Clinical Trials Group are developing a large-scale phase II trial and will study its metformin’s impact on recurrence in women treated for early stage breast cancer.
“There is a lot of interest in studying metformin in breast cancer, but so far we do not have direct evidence that metformin will improve outcomes in patients,” said Ligibel, who was not involved in the current study “That’s what this trial is for.”
So far, observational studies have suggested a lower risk of cancers, including breast cancer, and better response to chemotherapy in patients with diabetes who are treated with metformin, she said. Results of basic science studies have also suggested plausible biological mechanisms. The study from the Struhl lab suggests a potential new pathway through which metformin could have an effect on breast cancer cells, according to Ligibel.
In their search for compounds that selectively destroy cancer stem cells, researchers hope to improve cancer outcomes. But the story is never as simple in human cancers, according to Kornelia Polyak, M.D., Ph.D., a breast cancer researcher at the Dana-Farber Cancer Institute and an associate professor of medicine at Harvard Medical School.
Cancer stem cells are a shifty target, said Polyak, who was not involved in the current study. For example, any cancer cell can acquire the properties of a cancer stem cell, and cancer stem cells can change into non-stem cancer cells, which can be just as deadly. Clinical trials in people are needed to test these ideas, according to Polyak.
The study by Struhl and colleagues is an offshoot of a larger project in his lab to systematically track how gene activity changes when cells transform into cancer. These changes were remarkably similar to gene dynamics in diabetes and other inflammatory conditions.
The researchers reasoned that if a common genetic pathway underlies different diseases, drugs that work against one disease might work against another. In a screen, the most effective drug inhibiting the transformation of cells into cancer was metformin, which led to the experiments in this study. They were further encouraged by the low dose of metformin needed for the effect in the laboratory, compared to the amount needed for analogous molecular experiments in basic diabetes research. The relative dosage for treating or preventing cancer is unknown and untested in people.
Struhl and Harvard Medical School have applied for a patent for a combined therapy of metformin and a lower dose of chemotherapy, which is being tested in animals. The National Institutes of Health and the American Cancer Society funded this research.
The American Association for Cancer Research hosted a news briefing about the results of this study, on Monday, Sept. 14, 2009. Listen to a recording of the teleconference (http://media.libsyn.com/media/aacr/StemCell_Teleconferenc_Recording.mp3).
Panelists:
Moderator - Frank Rauscher, III, Ph.D.
Editor in Chief, Cancer Research
Professor, Gene Expression and Regulation Program
The Wistar Institute
Kevin Struhl, Ph.D.
David Wesley Gaiser Professor of Biological Chemistry and Molecular Pharmacology
Harvard Medical School
George Prendergast, Ph.D.
President, CEO and Professor
Lankenau Institute for Medical Research
Jennifer Ligibel, M.D.
Medical Oncologist
Dana-Farber Cancer Institute
Subscribe to the AACR news feed (http://feeds.feedburner.com/aacr)
Subscribe to the Cancer Research news feed (http://cancerres.aacrjournals.org/rss/recent.xml)
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes more than 28,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and nearly 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes six major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists. CR provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.
Media Contact:
Jeremy Moore
(267) 646-0557
Harvard Medical School
Carol Cruzan Morton
(617) 432-0442
# # #
MORE ARTICLES:
Resource Website Directory
A helpful directory of websites and other online resources.
To extend the lifeline of cancer patients - cancer, cancer, medicine - pharmaceutical industry
Current medical community does not fully understand the causes of cancer, we know that the carcinogenic factors are the following:
Lung Cancer: One of the Most Fatal Illnesses in the World
Lung cancer is one of the more prevalent kind of cancer Smoking is usually the culprit
Bone Cancer - Types of Bone Cancer
Bone cancer types of cancer are a subcategory of cancers which afflict the bones There can be two ways in which cancerous cells may affect the bones
Cancer Awareness Jewelry: Hope and Charm Bracelets
In recent years, the ongoing battle for a breast cancer cure has gained notoriety as more and more lives have become touched by the devastating emotional and physical trials of cancer Yet where the malignancy of cancer lurks, supportive movements such as the recent popularization of Cancer Awareness Jewelry prevail, helping to sustain the fight against the disease and fortify the battle for a cure
Breast Cancer in Men: The Warning Signs
Breast cancer is traditionally thought of as an exclusively female-related disease But like breast cancer in women, breast cancer in men is the uncontrolled growth of the cells of the breast tissue
St. Helena Hospital Cancer Center Affiliates with UCSF Medical Center to Enhance Local Cancer Treatment
The patient-centered, Martin-O'Neil Cancer Treatment Center at St. Helena Hospital offers world-class care, state-of-the-art technology and three types of oncology in one convenient location. The affiliation with the UCSF Helen Diller Family Comprehensive Cancer Center at UCSF Medical Center will provide North Bay patients with convenient access to cancer treatment specialists through a convenient Napa Valley location.
Cancer Risks and Health
Cancer is the second major cause of death in the United States More than half a million of us to die of cancer every year
Cancer - An Overview
Cancer is second only to cardiovascular disease as the leading cause of death in the Western world
Although Cancer is primarily a disease of the elderly with more than 60% of deaths from cancer occurring in those over the age of 65, cancer can strike even the youngest of children
Cholesterol and Cancer: Answers and Some New Questions
• Study shows low cholesterol as a symptom of cancer rather than a cause.
• Possible benefit of higher HDL and cancer risk.
• Lower cholesterol may lower risk of high-grade prostate cancer.
Commonly Asked Questions After Mesothelioma Treatment
There are some questions that will be on the mind of mesothelioma patients after the finish their course of therapyThe common questions are:
1- Can I be assured the cancer will never come back
What is a Cancer Registrar?
Do you know what a cancer registrar is? Chances are that you do not because cancer registrars represent a very small niche market in oncology healthcare and are usually found working behind-the-scenes.
Senators Chuck Hagel and Dianne Feinstein Make Lung Cancer Matter
June 25, 2008 marks a revolutionary day in history for anybody who cares about Lung Cancer, the Number One Cancer Killer in this country. It's almost tantamount to July 4th, Independence Day, for Lung Cancer. For the first time, in the last four decades, Lung Cancer finally has a voice, thanks to Senators Chuck Hagel, Dianne Feinstein and the tireless work over the last five years of Laurie Fenton, Sheila Ross and the Lung Cancer Alliance.
Men's Health Month: Recognize Your Individual Risk for Bladder Cancer
June is Men's Health Month. Bladder Cancer is more prevalent in men, especially military veterans, firefighters and cigarette smokers. The Men's Health Network offers information. Several physicians cite facts about the disease and insights on how to improve early detection.
Exposing the Double Standard of the Forgotten Cancer: Biggest Cancer Killer for Women and Men, Lung Cancer, Receives Least Research Funds
Lung Cancer Foundation of America (LCFA), , new organization trying to give the gift of life this holiday season by highlighting lack of research funding and providing critical support for lung cancer. Lung cancer remains biggest cancer killer for women and men yet receives least funds for research because lung cancer remains only cancer where victims are stigmatized and blamed for their disease.
